Pacific Biosciences of California Inc. [NASDAQ: PACB] price plunged by -2.16 percent to reach at -$0.24. The company report on September 7, 2023 at 9:05 AM that PacBio Announces Collaboration with Leading Library Preparation Automation Partners.
Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.
A sum of 3142742 shares traded at recent session while its average daily volume was at 3.59M shares. Pacific Biosciences of California Inc. shares reached a high of $11.055 and dropped to a low of $10.74 until finishing in the latest session at $10.86.
The one-year PACB stock forecast points to a potential upside of 30.3. The average equity rating for PACB stock is currently 2.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pacific Biosciences of California Inc. [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $15.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 05, 2023.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.52, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 18.41. The Price to Book ratio for the last quarter was 4.23, with the Price to Cash per share for the same quarter was set at 3.35.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.12. With this latest performance, PACB shares dropped by -9.42% in over the last four-week period, additionally plugging by 22.02% over the last 6 months – not to mention a rise of 98.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 43.97, with the RSI for the last a single of trading hit 46.12, and the three-weeks RSI is set at 43.48 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 12.13, while it was recorded at 11.16 for the last single week of trading, and 11.06 for the last 200 days.
Insight into Pacific Biosciences of California Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -237.58 and a Gross Margin at +38.08. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -244.92.
Return on Total Capital for PACB is now -18.70, given the latest momentum, and Return on Invested Capital for the company is -19.40. Return on Equity for this stock declined to -46.42, with Return on Assets sitting at -16.65. When it comes to the capital structure of this company, Pacific Biosciences of California Inc. [PACB] has a Total Debt to Total Equity ratio set at 168.59. Additionally, PACB Total Debt to Total Capital is recorded at 62.77, with Total Debt to Total Assets ending up at 53.70. Long-Term Debt to Equity for the company is recorded at 166.68, with the Long-Term Debt to Total Capital now at 62.06.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc. [PACB] managed to generate an average of -$408,645 per employee. Receivables Turnover for the company is 5.96 with a Total Asset Turnover recorded at a value of 0.07.Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.40.
PACB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
Pacific Biosciences of California Inc. [PACB] Institutonal Ownership Details
The top three institutional holders of PACB stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in PACB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in PACB stock with ownership which is approximately 5.7381%.